Behind the Scenes of Amgen's Latest Options Trends
Behind the Scenes of Amgen's Latest Options Trends
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.Investors with a lot of money to spend have taken a bullish stance on Amgen (NASDAQ:AMGN).
有大量資金的投資者對Amgen（納斯達克：安進）持看好態度。
And retail traders should know.
零售交易者應該知道。
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
我們在這裏追蹤的公開期權歷史記錄上看到交易時發現了這一點。
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AMGN, it often means somebody knows something is about to happen.
不管這些投資者是機構還是富有的個人，我們不得而知。但當AMGN發生如此重大的事件時，通常意味着有人知道即將發生的事情。
So how do we know what these investors just did?
那麼我們如何知道這些投資者剛剛做了什麼呢？
Today, Benzinga's options scanner spotted 8 uncommon options trades for Amgen.
今天，Benzinga的期權掃描器發現了Amgen的8筆異常期權交易。
This isn't normal.
這不正常。
The overall sentiment of these big-money traders is split between 50% bullish and 25%, bearish.
這些大資金交易者的整體情緒在50%看好和25%看淡之間分裂。
Out of all of the special options we uncovered, 6 are puts, for a total amount of $201,232, and 2 are calls, for a total amount of $119,247.
在我們發現的所有特殊期權中，有6個看跌期權，總額爲201,232美元，有2個看漲期權，總額爲119,247美元。
Predicted Price Range
預測價格區間
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $280.0 to $370.0 for Amgen over the recent three months.
根據交易活動，看起來重要投資者的目標是安進股票在最近三個月的價格區間，從280.0美元到370.0美元。
Volume & Open Interest Trends
成交量和未平倉量趨勢
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Amgen's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Amgen's substantial trades, within a strike price spectrum from $280.0 to $370.0 over the preceding 30 days.
評估成交量和未平倉合約是期權交易的戰略步驟。這些指標揭示了在指定行權價格下，安進期權的流動性和投資者興趣。即將公佈的數據將可視化地呈現了過去30天內，從280.0美元到370.0美元的行權價格範圍內，看跌期權和看漲期權的成交量和未平倉合約的波動，這與安進股票的大宗交易有關。
Amgen 30-Day Option Volume & Interest Snapshot
安進30天期權成交量和持倉量快照
Biggest Options Spotted:
最大的期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | CALL | SWEEP | BEARISH | 12/20/24 | $10.55 | $10.1 | $10.2 | $370.00 | $78.2K | 649 | 80 |
| AMGN | PUT | SWEEP | BULLISH | 10/18/24 | $7.1 | $5.55 | $6.3 | $335.00 | $48.5K | 628 | 46 |
| AMGN | CALL | TRADE | BEARISH | 10/18/24 | $59.45 | $58.55 | $58.55 | $280.00 | $40.9K | 89 | 7 |
| AMGN | PUT | SWEEP | NEUTRAL | 01/17/25 | $14.3 | $14.2 | $14.2 | $315.00 | $39.7K | 607 | 53 |
| AMGN | PUT | SWEEP | BULLISH | 10/04/24 | $3.45 | $3.25 | $3.25 | $332.50 | $32.5K | 4 | 100 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGN | 看漲 | SWEEP | 看淡 | 12/20/24 | $10.55 | $10.1 | $10.2 | $370.00 | $78.2千美元 | 649 | 80 |
| AMGN | 看跌 | SWEEP | 看好 | 10/18/24 | $7.1 | $5.55 | $6.3 | 335.00美元 | $48.5K | 628 | 46 |
| AMGN | 看漲 | 交易 | 看淡 | 10/18/24 | $59.45 | $58.55 | $58.55 | $280.00 | $40.9千 | 89 | 7 |
| AMGN | 看跌 | SWEEP | 中立 | 01/17/25 | $14.3 | 14.2 | 14.2 | $315.00 | $39.7K | 607 | 53 |
| AMGN | 看跌 | SWEEP | 看好 | 10/04/24 | $3.45 | $3.25 | $3.25 | $332.50 | $32.5K | 4 | 100 |
About Amgen
關於安進
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
安進是生物技術製藥領域的領導者。旗艦藥物包括增加紅細胞計數的艾普畢與阿拉尼許、增強免疫系統的奈帕姆和奈烏細胞移植因子、以及針對炎症性疾病的恩布瑞爾和歐特茲拉。安進在2006年推出了首個癌症治療藥物Vectibix，並推出了增強骨密度的藥物Prolia/Xgeva（於2010年獲批）和Evenity（於2019年獲批）。對Onyx的收購增強了該公司在治療腫瘤領域的藥物組合，其中包括Kyprolis。最近推出的藥物包括Repatha（降低膽固醇）、Aimovig（緩解偏頭痛）、Lumakras（治療肺癌）以及Tezspire（治療哮喘）。2023年Horizon收購帶來了幾種罕見疾病藥物，其中包括治療甲狀腺眼病的Tepezza。安進還擁有不斷增長的生物類似物組合。
In light of the recent options history for Amgen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
考慮到安進近期期權的歷史，現在適當關注該公司本身。我們旨在探討其當前業績。
Present Market Standing of Amgen
安進的當前市場狀況
- Currently trading with a volume of 759,929, the AMGN's price is up by 1.08%, now at $336.52.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 40 days.
- 目前成交量爲759,929股，AMGN股票價格上漲1.08%，目前爲336.52美元。
- RSI讀數表明該股目前可能接近超買水平。
- 預計業績發佈還有40天。
Unusual Options Activity Detected: Smart Money on the Move
檢測到期權異動：智慧資金在行動。
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
Benzinga Edge的期權異動模塊可以提前發現潛在的市場熱點。了解大筆的資金在您喜歡的股票上的倉位變動。點擊這裏獲取訪問權限。
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
期權與僅交易股票相比是一種更具風險的資產，但它們具有更高的利潤潛力。認真的期權交易者通過每日學習，進出交易，跟隨多個指標並密切關注市場來管理這種風險。
